跳至主要内容
临床试验/NCT01616615
NCT01616615已完成2 期

Aspirin for the Enhancement of Trophoblastic Invasion in Women With Abnormal Uterine Artery Doppler at 11-14 Weeks of Gestation

Sara Varea3 个研究点 分布在 1 个国家目标入组 190 人开始时间: 2012年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
190
试验地点
3
主要终点
Uterine artery mean pulsatility

研究概览

简要总结

To establish wether a prophylactic intervention from first trimester with low-dose of aspirin improves trophoblastic invasion evaluated at third trimester in women defined as high-risk by abnormal uterine artery Doppler at first trimester

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Patients over 18 years old attending for routine ultrasound at first trimester of pregnancy between 11 and 14 weeks of gestation (Crown-to rump length 45-48mm)
  • Single gestation
  • Mean pulsatility index of the uterine arteries above the 95th percentile for our population

排除标准

  • Pre-existing hypertension, renal or cardiovascular disease
  • previous history of pre-eclampsia
  • Pregestational diabetes
  • Systemic lupus Erythematosus
  • Gastric ulcer
  • Acetylsalicylic acid or lactose hypersensitivity
  • Bleeding disorders
  • Fetal disorders (including chromosomal abnormalities)
  • Administration of low molecular weight heparin
  • Concomitant treatment with aspirin

研究组 & 干预措施

ASPIRIN

Experimental

150 mg milligram(s)/ day oral use

干预措施: Aspirin (Drug)

PLACEBO

Placebo Comparator

干预措施: placebo (Drug)

结局指标

主要结局

Uterine artery mean pulsatility

时间窗: at 28 weeks of gestation

次要结局

  • Pre-eclampsia(delivery)
  • Severe preeclampsia(at delivery)
  • Intrauterine Growth Retardation(at delivery)
  • Significant neonatal morbidity(at delivery)
  • number of cesarean(at delivery)
  • Neonatal acidosis(at delivery)
  • Perinatal mortality(28 days post partum)
  • Days in the Neonatal Intensive Care Unit(28 days post partum)

研究者

发起方
Sara Varea
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Sara Varea

Clinical Trial Manager

Fundacion Clinic per a la Recerca Biomédica

研究点 (3)

Loading locations...

相似试验